A small double-blind placebo-controlled crossover trial conducted in the Netherlands, published in 2000, demonstrated reductions in HbA1c, weight and insulin dose requirement when metformin was added to treatment for 5 months in insulin-treated type 2 diabetes [29]. Here, INS is linked to type 2 diabetes mellitus.